Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia

Journal of Hematology and Oncology

Volumn 3, Issue , 2010, Pages

  Pidala, Joseph ^a,b   Kim, Jongphil ^a,b   Anasetti, Claudio ^a,b   Kharfan Dabaja, Mohamed A ^a,b   Nishihori, Taiga ^a,b   Field, Teresa ^a,b   Perkins, Janelle ^a,b   Perez, Lia ^a,b   Fernandez, Hugo F ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; DRUG DERIVATIVE; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; CANCER MORTALITY; CANCER REGRESSION; CHRONIC GRAFT VERSUS HOST DISEASE; HUMAN; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PNEUMONIA; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; ALLOTRANSPLANTATION; AREA UNDER THE CURVE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY;

AREA UNDER CURVE; BUSULFAN; CYCLOPHOSPHAMIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 77957294297     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-3-36     Document Type: Article

References (24)

1. Association of busulfan area under the curve with veno-occlusive disease following BMT. SP Dix JR Wingard RE Mullins I Jerkunica TG Davidson CE Gilmore RC York LS Lin SM Devine RB Geller LT Heffner CD Hillyer HK Holland EF Winton R Saral, Bone Marrow Transplant 1996 17 225 230 8640171
2. Busulfan in hematopoietic stem cell transplant setting. JS McCune LA Holmberg, Expert Opin Drug Metab Toxicol 2009 5 957 969 10.1517/ 17425250903107764 19611402
3. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. GB McDonald JT Slattery ME Bouvier S Ren AL Batchelder TF Kalhorn HG Schoch C Anasetti T Gooley, Blood 2003 101 2043 2048 10.1182/blood-2002-06-1860 12406916
4. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. M Bornhauser B Storer JT Slattery FR Appelbaum HJ Deeg J Hansen PJ Martin GB McDonald WG Nichols J Radich A Woolfrey A Jenke E Schleyer C Thiede G Ehninger C Anasetti, Blood 2003 102 820 826 10.1182/blood-2002-11-3567 12676781 (Pubitemid 36917770)
5. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. M de Lima D Couriel PF Thall X Wang T Madden R Jones EJ Shpall M Shahjahan B Pierre S Giralt M Korbling JA Russell RE Champlin BS Andersson, Blood 2004 104 857 864 10.1182/blood-2004-02-0414 15073038
6. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. JA Russell HT Tran D Quinlan A Chaudhry P Duggan C Brown D Stewart JD Ruether D Morris S Glick E Gyonyor BS Andersson, Biol Blood Marrow Transplant 2002 8 468 476 10.1053/bbmt.2002.v8.pm12374451 12374451
7. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. S Tauro C Craddock K Peggs G Begum P Mahendra G Cook J Marsh D Milligan A Goldstone A Hunter A Khwaja R Chopra T Littlewood A Peniket A Parker G Jackson G Hale M Cook N Russell S Mackinnon, J Clin Oncol 2005 23 9387 9393 10.1200/JCO.2005.02.0057 16314618
8. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. K van Besien A Artz S Smith D Cao S Rich L Godley D Jones P Del Cerro D Bennett B Casey O Odenike M Thirman C Daugherty A Wickrema T Zimmerman RA Larson W Stock, J Clin Oncol 2005 23 5728 5738 10.1200/JCO.2005.15.602 16009946
9. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. C Schmid M Schleuning G Ledderose J Tischer HJ Kolb, J Clin Oncol 2005 23 5675 5687 10.1200/JCO.2005.07.061 16110027
10. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. C Schmid M Schleuning M Hentrich GE Markl A Gerbitz J Tischer G Ledderose D Oruzio W Hiddemann HJ Kolb, Bone Marrow Transplant 2008 41 721 727 10.1038/sj.bmt.1705965 18176613
11. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. C Schmid M Schleuning R Schwerdtfeger B Hertenstein E Mischak-Weissinger D Bunjes SV Harsdorf C Scheid U Holtick H Greinix F Keil B Schneider M Sandherr G Bug J Tischer G Ledderose M Hallek W Hiddemann HJ Kolb, Blood 2006 108 1092 1099 10.1182/blood-2005-10-4165 16551971
12. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. DP Blaise J Michel Boiron C Faucher M Mohty JO Bay VJ Bardoux V Perreau D Coso A Pigneux N Vey, Cancer 2005 104 1931 1938 10.1002/cncr.21418 16178004 (Pubitemid 41513177)
13. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. HG Sayer M Kroger J Beyer M Kiehl SA Klein K Schaefer-Eckart R Schwerdtfeger W Siegert V Runde C Theuser H Martin J Schetelig DW Beelen A Fauser J Kienast K Hoffken G Ehninger M Bornhauser, Bone Marrow Transplant 2003 31 1089 1095 10.1038/sj.bmt.1704062 12796788
14. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. A Shimoni I Hardan N Shem-Tov M Yeshurun R Yerushalmi A Avigdor I Ben-Bassat A Nagler, Leukemia 2006 20 322 328 10.1038/sj.leu.2404037 16307018
15. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. D Valcarcel R Martino D Caballero J Martin C Ferra JB Nieto A Sampol MT Bernal JL Pinana L Vazquez JM Ribera J Besalduch JM Moraleda D Carrera MS Brunet JA Perez-Simon J Sierra, J Clin Oncol 2008 26 577 584 10.1200/JCO.2007.11.1641 18086801
16. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. E Carreras H Bertz W Arcese JP Vernant JF Tomas H Hagglund G Bandini H Esperou J Russell J de la Rubia G Di Girolamo H Demuynck O Hartmann J Clausen T Ruutu V Leblond A Iriondo A Bosi I Ben-Bassat V Koza A Gratwohl JF Apperley, Blood 1998 92 3599 3604 9808553
17. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. GB McDonald MS Hinds LD Fisher HG Schoch JL Wolford M Banaji BJ Hardin HM Shulman RA Clift, Ann Intern Med 1993 118 255 267 8420443
18. -1994 Consensus Conference on Acute GVHD Grading. D Przepiorka D Weisdorf P Martin HG Klingemann P Beatty J Hows ED Thomas, Bone Marrow Transplant 1995 15 825 828 7581076
19. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. AH Filipovich D Weisdorf S Pavletic G Socie JR Wingard SJ Lee P Martin J Chien D Przepiorka D Couriel EW Cowen P Dinndorf A Farrell R Hartzman J Henslee-Downey D Jacobsohn G McDonald B Mittleman JD Rizzo M Robinson M Schubert K Schultz H Shulman M Turner G Vogelsang ME Flowers, Biol Blood Marrow Transplant 2005 11 945 956 10.1016/j.bbmt.2005.09.004 16338616 (Pubitemid 41754712)
20. class of K-sample tests for comparing the cumulative incidence of a competing risk. RA Gray, Annals Of Statistics 1988 16 1141 1154 10.1214/aos/1176350951
21. A proportional hazards model for the subdistribution of a competing risk. JA Fine, JASA 1999 94 496 509
22. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. BS Andersson M de Lima PF Thall X Wang D Couriel M Korbling S Roberson S Giralt B Pierre JA Russell EJ Shpall RB Jones RE Champlin, Biol Blood Marrow Transplant 2008 14 672 684 10.1016/j.bbmt.2008.03. 009 18489993
23. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. CN Bredeson MJ Zhang MA Agovi A Bacigalupo NJ Bahlis K Ballen C Brown MA Chaudhry MM Horowitz S Kurian D Quinlan CE Muehlenbien JA Russell L Savoie JD Rizzo DA Stewart, Biol Blood Marrow Transplant 2008 14 993 1003 10.1016/j.bbmt.2008.06.009 18721762
24. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. YS Chae SK Sohn JG Kim YY Cho JH Moon HJ Shin JS Chung GJ Cho DH Yang JJ Lee YK Kim HJ Kim, Bone Marrow Transplant 2007 40 541 547 10.1038/sj.bmt.1705770 17637692